Skip to main content
. Author manuscript; available in PMC: 2018 Jun 15.
Published in final edited form as: Clin Cancer Res. 2016 Dec 23;23(12):2981–2990. doi: 10.1158/1078-0432.CCR-16-1887

Figure 5. In vivo.

Figure 5

efficacy of RXDX-105 in a PDX model of CRC harboring NCOA4-RET fusion. A, Tumor growth inhibition by RXDX-105 orally administered BID at 10 and 30 mg/kg. Tumor sizes are presented as average ±SEM (*, P < 0.05; **, P < 0.01). B, Plot of percentage change of individual tumor volume compared with baseline. The y-axis of individual tumor responses represents “% of change from start.”